Dr. René Aerts is the Founder of RA-Consultancy BV and currently serves as Partner at NovioCap BV. He retired from Merck/MSD Animal Health in 2013 where he had been a member of the Executive Committee since 2008 as Global Head Vaccine Research. He previous held senior positions in Manufacturing Operations, Regulatory Affairs and R&D at Intervet International. He holds non-executive and Advisory Board positions at AGC Biologics (USA), The Jenner Institute (UK), ImmunoValley (NL), Schothorst Feed Research BV (NL) and Alternative Gene Expression Ltd (ES). Mr. Aerts received a PhD in Bioanalytics and Pharmacochemistry from the Free University of Amsterdam in 1990.
Roberto Barzi is an investor in the healthcare sector, where he has been active for the past decade. Originally part of 3i’s global healthcare team, he later founded Fort Rock Capital, a specialist investor in the space. He is the Managing Partner of VitaTech (lifesciences), based in Luxembourg and active across Europe. He currently serves on the boards of Vasopharm GmbH (Germany, traumatic brain injury), GNS Healthcare (USA, AI and digital health) and Medinet (UK, clinical services).
Claudia D’Augusta has over 20 years of experience in corporate finance, 14 of which have been in the life sciences sector. She currently serves as CFO of Therachon, a Swiss clinical-stage biotechnology company focused on the discovery, development and commercialization of innovative treatments for serious rare conditions. Prior to this she served as CFO at TiGenix, a biopharmaceutical company that developed Alofisel, the first allogenic stem cell product to receive marketing authorization for the treatment of perianal fistulas in Crohn's patients, and was acquired by Takeda in 2018. Claudia currently also serves as Venture Partner at Ysios Capital Partners (ES) as well as on the Board of Bone Therapeutics (BE) and Reneuron (UK). She holds a bachelor's degree in economics and a Ph.D. in Business Administration from Bocconi University in Milan.
Jean Stéphenne is a highly-experienced life sciences executive, who has served in senior leadership roles at a large number of biotechnology and pharmaceutical companies, most recently as Chairman of TiGenix (acquired by Takeda in 2018). Jean was previously a Member of the Corporate Executive Team of GlaxoSmithKline (GSK) and Chief Executive of GSK Biologicals (now GSK Vaccines). During his 40-year tenure, he grew a company of 50 people into a fully integrated worldwide leader in vaccine development, with 12,000 employees. He currently serves on the Board of various life sciences companies including Vaxxilon (DE), OncoDNA (BE), BoneTherapeutics (BE), CureVac (DE) and Bepharbel (BE) as well as in biotech investments funds Vesalius (BE) and Merieux Investments (FR). For his contribution to the Belgian economy and global public health, he has received diverse business recognitions and was honored with various titles by the Belgian and British governments.
Nicola Zambon has 23 years of M&A and principal investment experience. He is the founder and managing partner of Cleon Capital, an independent advisory and investment company with offices in Madrid and Milan. Prior to founding Cleon, he served as director and partner of the private equity firms Investindustrial and Ergon Capital. Nicola is a board member of 15 companies located in various jurisdictions across Europe.